VYNE Therapeutics Inc. (VYNE)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 100 | 202 | 121 | 198 |
| Total revenues | 69 | - | - | - |
| Research and development | 4,881 | 6,124 | 10,248 | 7,306 |
| General and administrative | 2,730 | 3,275 | 2,964 | 3,288 |
| Total operating expenses | 7,611 | 9,399 | 13,212 | 10,594 |
| Operating loss | -7,542 | -9,197 | -13,091 | -10,396 |
| Other income, net | 1,795 | 594 | 934 | 1,001 |
| Loss from continuing operations before income taxes | -5,747 | -8,603 | -12,157 | -9,395 |
| Income tax expense | - | - | - | - |
| Loss from continuing operations | -5,747 | -8,603 | -12,157 | -9,395 |
| Loss from discontinued operations, net of income taxes | -8 | -8 | - | -11 |
| Net loss | -5,755 | -8,611 | -12,157 | -9,406 |
| Unrealized (losses) gains on marketable securities, net of tax of 0 | -2 | -20 | 92 | 12 |
| Total other comprehensive (loss) gain | -2 | -20 | 92 | 12 |
| Comprehensive loss | -5,757 | -8,631 | -12,065 | -9,394 |
| Loss per share, basic (in dollars per share) | -0.13 | -0.2 | -0.29 | -0.22 |
| Loss per share, diluted (in dollars per share) | -0.13 | -0.2 | -0.29 | -0.22 |
| Weighted average shares outstanding - basic (in shares) | 42,759,000 | 42,673,000 | 42,587,000 | 42,586,000 |
| Weighted average shares outstanding - diluted (in shares) | 42,759,000 | 42,673,000 | 42,587,000 | 42,586,000 |